Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
Résultats de la recherche
Tout
-
Experienced leader in radiopharmaceutical drug development, regulatory, and clinical strategies will advance ITM’s broad pipeline and clinical development strategy Garching / Munich, Germany, April...
-
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
-
PALM BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts see the global radiotherapy market continuing to grow in the years to come. A recent report...
-
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
-
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Robotic Radiotherapy Market by Product, by Technology, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
-
Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
-
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
-
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
-
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
-
Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...